Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.355 - [histone H3]-lysine9 N-trimethyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.
Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.
Enhancer of Zeste Homolog 2 Silences MicroRNA-218 in Human Pancreatic Ductal Adenocarcinoma Cells by Inducing Formation of Heterochromatin.
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy.
Histone Methyltransferases Useful in Gastric Cancer Research.
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.
Robust expression of EZH2 in endocervical neoplastic lesions.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
Adenocarcinoma of Lung
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.
Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Hypoxic tumor-derived exosomal circular RNA SETDB1 promotes invasive growth and EMT via the miR-7/Sp1 axis in lung adenocarcinoma.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Adenoma
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
Alzheimer Disease
Inhibition of EHMT1/2 rescues synaptic and cognitive functions for Alzheimer's disease.
Two conserved epigenetic regulators prevent healthy ageing.
Anhedonia
Setdb1 histone methyltransferase regulates mood-related behaviors and expression of the NMDA receptor subunit NR2B.
Anus, Imperforate
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Arthritis, Rheumatoid
Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis.
Asthma
An efficient hybrid feature selection method to identify potential biomarkers in common chronic lung inflammatory diseases.
An epigenetic silencing pathway controlling T helper 2 cell lineage commitment.
Astrocytoma
Histone Mark Profiling in Pediatric Astrocytomas Reveals Prognostic Significance of H3K9 Trimethylation and Histone Methyltransferase SUV39H1.
Atherosclerosis
Histone Methyltransferase Enhancer of Zeste Homolog 2-Mediated ABCA1 Promoter DNA Methylation Contributes to the Progression of Atherosclerosis.
Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.
Autoimmune Diseases
Histone methyltransferase ash1l suppresses interleukin-6 production and inflammatory autoimmune diseases by inducing the ubiquitin-editing enzyme a20.
Avian Leukosis
Targeting the Histone Methyltransferase Disruptor of Telomeric Silencing 1-Like Restricts Avian Leukosis Virus Subgroup J Replication by Restoring the Innate Immune Response in Chicken Macrophages.
Bacterial Infections
Signatures of selection reveal candidate genes involved in economic traits and cold acclimation in five Swedish cattle breeds.
Biliary Tract Neoplasms
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
Blast Crisis
Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia.
Blister
The CURLY LEAF interacting protein BLISTER controls expression of polycomb-group target genes and cellular differentiation of Arabidopsis thaliana.
Bone Marrow Failure Disorders
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation.
Brain Injuries
Post-Treatment Sevoflurane Protects Against Hypoxic-Ischemic Brain Injury in Neonatal Rats by Downregulating Histone Methyltransferase G9a and Upregulating Nuclear Factor Erythroid 2-Related Factor 2 (NRF2).
Brain Ischemia
Inhibition of histone methyltransferases SUV39H1 and G9a leads to neuroprotection in an in vitro model of cerebral ischemia.
Brain Neoplasms
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
HP1? is highly expressed in glioma cells and facilitates cell proliferation and survival.
[Epigenetic analyses of brain tumor stem cells]
Breast Neoplasms
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor.
DOT1L histone methyltransferase regulates the expression of BCAT1 and is involved in sphere formation and cell migration of breast cancer cell lines.
Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.
Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.
EHMT2 is a metastasis regulator in breast cancer.
EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
G9a-mediated repression of CDH10 in hypoxia enhances breast tumour cell motility and associates with poor survival outcome.
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Histone Methyltransferase EZH2 Induces Akt-Dependent Genomic Instability and BRCA1 Inhibition in Breast Cancer.
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.
Impact of histone methyltransferase SUV420H2 in breast cancer.
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.
Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.
Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
Inhibition of histone methyltransferase DOT1L silences ER? gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance.
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Loss of DNA Methylation and Histone H4 Lysine 20 Trimethylation in Human Breast Cancer Cells is Associated with Aberrant Expression of DNA Methyltransferase 1, Suv4-20h2 Histone Methyltransferase and Methyl-Binding Proteins.
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
microRNA-7 suppresses the invasive potential of breast cancer cells and sensitizes cells to DNA damages by targeting histone methyltransferase SET8.
MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Novel strategies for molecular targeting to cancer.
PRMT2 and ROR? expression are associated with breast cancer survival outcomes.
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Pygo2 associates with MLL2 histone methyltransferase (HMT) and GCN5 histone acetyltransferase (HAT) complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion.
RNA-seq based transcriptome analysis of EHMT2 functions in breast cancer.
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 induces epithelial?mesenchymal transition in breast carcinoma by directly binding with Snail promoter.
SETDB1 regulates SMAD7 expression for breast cancer metastasis.
Setdb1, a novel interactor of ?Np63, is involved in breast tumorigenesis.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3.
The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis.
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
Carcinogenesis
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Abnormal overexpression of G9a in melanoma cells promotes cancer progression via upregulation of the Notch1 signaling pathway.
Altered telomere homeostasis and resistance to skin carcinogenesis in Suv39h1 transgenic mice.
Arsenic and benzo[a]pyrene co-exposure acts synergistically in inducing cancer stem cell-like property and tumorigenesis by epigenetically down-regulating SOCS3 expression.
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
c-Rel regulates Ezh2 expression in activated lymphocytes and malignant lymphoid cells.
Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.
Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication.
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Effect of SMYD3 on the microRNA expression profile of MCF-7 breast cancer cells.
Effects of SMYD3 over-expression on cell cycle acceleration and cell proliferation in MDA-MB-231 human breast cancer cells.
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Emerging role of SETDB1 as a therapeutic target.
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis.
Epigenetic Modifier SETD8 as a Therapeutic Target for High-Grade Serous Ovarian Cancer.
EZH2 Downregulation Augments the Effect of Irradiation in Reducing Pancreatic Cancer Cell Proliferation in vitro.
Fine-tuning AKT kinase activity through direct lysine methylation.
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
GSK3? inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro.
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
In utero exposure to diethylstilbestrol (DES) or bisphenol-A (BPA) increases EZH2 expression in the mammary gland: an epigenetic mechanism linking endocrine disruptors to breast cancer.
Increased Expression of EZH2 in Merkel Cell Carcinoma Is Associated with Disease Progression and Poorer Prognosis.
Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
JAK signaling globally counteracts heterochromatic gene silencing.
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Monomethyltransferase SET8 facilitates hepatocellular carcinoma growth by enhancing aerobic glycolysis.
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis.
Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
Novobiocin decreases SMYD3 expression and inhibits the migration of MDA-MB-231 human breast cancer cells.
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Rb Regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation.
Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects?
SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells.
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
Setdb1, a novel interactor of ?Np63, is involved in breast tumorigenesis.
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
SMYD2-dependent HSP90 methylation promotes cancer cell proliferation by regulating the chaperone complex formation.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Surveillance of Retroelement Expression and Nucleic-Acid Immunity by Histone Methyltransferase SETDB1.
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation.
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
The c-MYC-BMI1 axis is essential for SETDB1-mediated breast tumourigenesis.
The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.
The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3.
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
VHL-HIF-2? axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
[Histone methylation and its relationship with cancer].
Carcinoma
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
Elevated expression of coactivator-associated arginine methyltransferase 1 is associated with early hepatocarcinogenesis.
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Enhancer of Zeste Homolog 2 Expression Is Associated With Metastasis and Adverse Clinical Outcome in Clear Cell Renal Cell Carcinoma: A Comparative Study and Review of the Literature.
Enhancing response to immunotherapy in urothelial carcinoma by targeted inhibition of the histone methyltransferase G9a pathway.
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver.
Histone methyltransferase SET8 is regulated by miR-192/215 and induces oncogene-induced senescence via p53-dependent DNA damage in human gastric carcinoma cells.
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas.
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis.
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas.
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
[DZNep raises miR-200c expression to delay the invasion and migration of MGC-803 gastric carcinoma cells].
Carcinoma, Adenoid Cystic
Knockdown of Histone Methyltransferase WHSC1 Induces Apoptosis and Inhibits Cell Proliferation and Tumorigenesis in Salivary Adenoid Cystic Carcinoma.
Carcinoma, Hepatocellular
A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome.
A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers.
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months.
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Downregulation of histone methyltransferase SET8 inhibits progression of hepatocellular carcinoma.
Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma.
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c.
Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Histone Methyltransferase G9a-Promoted Progression of Hepatocellular Carcinoma Is Targeted by Liver-Specific Hsa-miR-122.
Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Knockdown of Histone Methyltransferase hSETD1A Inhibits Progression, Migration, and Invasion in Human Hepatocellular Carcinoma.
MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas.
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
TERT promoter mutations in primary liver tumors.
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
[Effect of Basil Polysaccharide on Histone H3K9me2 Methylation and Expression of G9a and JMJD1A in Hepatoma Cells Under Hypoxic Conditions].
Carcinoma, Merkel Cell
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Carcinoma, Non-Small-Cell Lung
A regulatory circuitry comprising TP53, miR-29 family, and SETDB1 in non-small cell lung cancer.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition.
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
MiR-520a-3p inhibits malignant progression of epithelial ovarian cancer by targeting SUV39H1 expression.
Carcinoma, Renal Cell
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.
Carcinoma, Small Cell
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
Carcinoma, Squamous Cell
A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Histone Methyltransferase NSD3 Is a Lung Squamous Cell Carcinoma Driver.
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Cardiomegaly
Chromatin modifications remodel cardiac gene expression.
Histone Methyltransferase G9a is Required for Cardiomyocyte Homeostasis and Hypertrophy.
Histone Methyltransferase SET1 Mediates Angiotensin II-Induced Endothelin-1 Transcription and Cardiac Hypertrophy in Mice.
Interplay of chromatin modifications and non-coding RNAs in the heart.
Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy.
Six1 is down-regulated in end-stage human dilated cardiomyopathy independently of Ezh2.
Cardiomyopathies
ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Correction to: ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Cardiomyopathy, Dilated
H3K9 histone methyltransferase G9a ameliorates dilated cardiomyopathy via the downregulation of cell adhesion molecules.
The Histone Methyltransferase Mixed Lineage Leukemia (MLL) 3 May Play a Potential Role on Clinical Dilated Cardiomyopathy.
Cardiovascular Diseases
EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Carotid Artery Injuries
Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.
Central Nervous System Diseases
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Chagas Disease
Antiproliferative effects of delta 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies.
CHARGE Syndrome
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Cholangiocarcinoma
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3.
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator.
Choline Deficiency
Gestational choline supply regulates methylation of histone H3, expression of histone methyltransferases G9a (Kmt1c) and Suv39h1 (Kmt1a), and DNA methylation of their genes in rat fetal liver and brain.
Chondrosarcoma
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
Classical Swine Fever
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
Cleft Palate
Retinoic acid inhibits histone methyltransferase Whsc1 during palatogenesis.
Cockayne Syndrome
Activation of RNA polymerase I transcription by cockayne syndrome group B protein and histone methyltransferase G9a.
Cockayne syndrome group B deficiency reduces H3K9me3 chromatin remodeler SETDB1 and exacerbates cellular aging.
Colitis
Gut stem cell necroptosis by genome instability triggers bowel inflammation.
Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation.
The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis.
Colonic Neoplasms
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
KDM5c inhibits multidrug resistance of colon cancer cell line by down-regulating ABCC1.
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
Novel strategies for molecular targeting to cancer.
Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells.
Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma.
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
Colorectal Neoplasms
Association of the SUV39H1 histone methyltransferase with the DNA methyltransferase 1 at mRNA expression level in primary colorectal cancer.
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
Cancer-associated upregulation of histone H3 lysine 9 trimethylation promotes cell motility in vitro and drives tumor formation in vivo.
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene.
G9a controls pluripotent-like identity and tumor-initiating function in human colorectal cancer.
Genetic Variants of Methyl Metabolizing Enzymes and Epigenetic Regulators: Associations with Promoter CpG Island Hypermethylation in Colorectal Cancer.
Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation through the STAT1-CCND1/CDK6 Axis.
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Histone methyltransferase WHSC1 inhibits colorectal cancer cell apoptosis via targeting anti-apoptotic BCL2.
Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells.
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
Network Inference Analysis Identifies SETDB1 as a Key Regulator for Reverting Colorectal Cancer Cells into Differentiated Normal-Like Cells.
Notch1 counteracts WNT/?-catenin signaling through chromatin modification in colorectal cancer.
NSD1 encoding a histone methyltransferase exhibits frameshift mutations in colorectal cancers.
Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
SMYD3 tandem repeats polymorphism is not associated with the occurrence and metastasis of hepatocellular carcinoma in a Chinese population.
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
Coronary Disease
Novel epigenetic-sensitive clinical challenges both in type 1 and type 2 diabetes.
COVID-19
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Crohn Disease
Gut stem cell necroptosis by genome instability triggers bowel inflammation.
Cysts
dSETDB1 and SU(VAR)3-9 sequentially function during germline-stem cell differentiation in Drosophila melanogaster.
Histone methyltransferase 1 regulates the encystation process in the parasite Giardia lamblia.
Diabetes Mellitus
Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 1
Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes.
Histone H2AK119 and H2BK120 Monoubiquitination Modulate SET7/9 and SUV39H1 in Type 1 Diabetes Induced Renal Fibrosis.
Type 1 Diabetes and the HLA Region: Genetic Association Besides Classical HLA Class II Genes.
Diabetes Mellitus, Type 2
Adverse epigenetic signatures by histone methyltransferase set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus.
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
The Histone Methyltransferase MLL1 Directs Macrophage-Mediated Inflammation in Wound Healing and Is Altered in a Murine Model of Obesity and Type 2 Diabetes.
Diabetes, Gestational
Gestational Diabetes Mellitus Impairs Fetal Endothelial Cell Functions Through a Mechanism Involving MicroRNA-101 and Histone Methyltransferase Enhancer of Zester Homolog-2.
Diabetic Cardiomyopathies
MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabetic cardiomyopathy.
Down Syndrome
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
PRDM8 reveals aberrant DNA methylation in aging syndromes and is relevant for hematopoietic and neuronal differentiation.
Dyskeratosis Congenita
DNA methylation in PRDM8 is indicative for dyskeratosis congenita.
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
Dystonia
Corrigendum: Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Generalized dystonia associated with mutation in the histone methyltransferase gene KMT2B (DYT28) and white matter abnormalities.
Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia.
Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype-phenotype correlations of all published cases.
Identification of Novel KMT2B Variants in Chinese Dystonia Patients via Whole-Exome Sequencing.
Mutations in the histone methyltransferase gene KMT2B cause complex early-onset dystonia.
Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.
Review of the phenotype of early-onset generalised progressive dystonia due to mutations in KMT2B.
Encephalomyelitis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Encephalomyelitis, Autoimmune, Experimental
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Endometrial Neoplasms
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
Oncogenic histone methyltransferase EZH2: A novel prognostic marker with therapeutic potential in endometrial cancer.
SETDB1 in cancer: overexpression and its therapeutic implications.
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
Endometriosis
Effects of histone methyltransferase inhibition in endometriosis.
Inhibition of Histone Methyltransferase EZH2 Suppresses Endometriotic Vesicle Development in a Rat Model of Endometriosis.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Esophageal Squamous Cell Carcinoma
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Foot-and-Mouth Disease
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Friedreich Ataxia
Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich's ataxia patient cells.
Ganglioglioma
Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with ganglioglioma.
Gastrointestinal Diseases
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Genetic Diseases, Inborn
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
Kleefstra syndrome: Recurrence in siblings due to a paternal mosaic mutation.
Pulmonary hypertension in patients with 9q34.3 microdeletion-associated Kleefstra syndrome.
Glioblastoma
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
Epigenetic Deregulation of the Histone Methyltransferase KMT5B Contributes to Malignant Transformation in Glioblastoma.
Novel strategies for molecular targeting to cancer.
SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
Glioma
A central role for MeCP2 in the epigenetic repression of miR-200c during epithelial-to-mesenchymal transition of glioma.
BIX01294, an inhibitor of histone methyltransferase, induces autophagy-dependent differentiation of glioma stem-like cells.
Cancer Stem Cells Activate STAT3 the EZ Way.
EGFR promoter exhibits dynamic histone modifications and binding of ASH2L and P300 in human germinal matrix and gliomas.
Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
ENHANCER OF ZESTE 2 (EZH2) IS UP-REGULATED IN MALIGNANT GLIOMAS AND IN GLIOMA STEM-LIKE CELLS.
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.
Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity.
EZH2-Inhibited MicroRNA-454-3p Promotes M2 Macrophage Polarization in Glioma.
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Histone methyltransferase SUV39H2 regulates cell growth and chemosensitivity in glioma via regulation of hedgehog signaling.
HP1? is highly expressed in glioma cells and facilitates cell proliferation and survival.
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Pygo2 functions as a prognostic factor for glioma due to its up-regulation of H3K4me3 and promotion of MLL1/MLL2 complex recruitment.
Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation.
SETDB1 in cancer: overexpression and its therapeutic implications.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
Graft vs Host Disease
Analysis of Relationships between Immune Checkpoint and Methylase Gene Polymorphisms and Outcomes after Unrelated Bone Marrow Transplantation.
The histone methyltransferase Ezh2 is a crucial epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host disease.
Growth Hormone-Secreting Pituitary Adenoma
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Head and Neck Neoplasms
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma.
Hearing Loss
CHARGE and Kabuki syndromes: A phenotypic and molecular link.
Inhibition of Histone Methyltransferase G9a Attenuates Noise-Induced Cochlear Synaptopathy and Hearing Loss.
Heart Defects, Congenital
G9?-dependent histone H3K9me3 hypomethylation promotes overexpression of cardiomyogenesis-related genes in foetal mice.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Heart Diseases
The promising therapeutic agents for heart diseases: Histone Methyltransferase inhibitors.
Heart Failure
The chromatin-binding protein Smyd1 restricts adult mammalian heart growth.
The histone 3 lysine 9 methyltransferase inhibitor chaetocin improves prognosis in a rat model of high salt diet-induced heart failure.
Hematologic Neoplasms
Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3).
[Advances of Researches on the Role of Histone Modification in Hematological Neoplasms].
Hepatitis
Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.
Hepatitis B
HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase.
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
Hepatitis B, Chronic
Genetic association of human leukocyte antigens with chronicity or resolution of hepatitis B infection in thai population.
Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study.
Herpes Simplex
Barrier-to-Autointegration Factor 1 (BAF/BANF1) Promotes Association of the SETD1A Histone Methyltransferase with Herpes Simplex Virus Immediate-Early Gene Promoters.
Huntington Disease
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Hyperalgesia
Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.
Hyperglycemia
High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy.
Hypersensitivity
Contribution of the Suppressor of Variegation 3-9 Homolog 1 in Dorsal Root Ganglia and Spinal Cord Dorsal Horn to Nerve Injury-induced Nociceptive Hypersensitivity.
Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression.
Histone H3 lysine 36 methyltransferase mobilizes NER factors to regulate tolerance against alkylation damage in fission yeast.
Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack.
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Hypertension
Genomic analysis of the domestication and post-Spanish conquest evolution of the llama and alpaca.
Hypertrichosis
Broad neurodevelopmental features and cortical anomalies associated with a novel de novo KMT2A variant in Wiedemann-Steiner syndrome.
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Hypogonadism
Hypogonadotropic Hypogonadism and Kleefstra Syndrome due to a Pathogenic Variant in the EHMT1 Gene: An Underrecognized Association.
Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells.
Infections
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases.
Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells.
Histone methyltransferase SUV39H1 participates in host defense by methylating mycobacterial histone-like protein HupB.
Host genetic variants influencing the clinical course of hepatitis B virus infection.
IFI16, a nuclear innate immune DNA sensor, mediates epigenetic silencing of herpesvirus genomes by its association with H3K9 methyltransferases SUV39H1 and GLP.
Nitric oxide and KLF4 protein epigenetically modify class II transactivator to repress major histocompatibility complex II expression during Mycobacterium bovis bacillus Calmette-Guerin infection.
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.
SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases.
SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9.
Testosterone response of hepatic gene expression in female mice having acquired testosterone-unresponsive immunity to Plasmodium chabaudi malaria.
Transcriptional Derepression of the ERVWE1 Locus following Influenza A Virus Infection.
Infertility
A team of heterochromatin factors collaborates with small RNA pathways to combat repetitive elements and germline stress.
Prdm9 inter-subspecific interactions in hybrid male sterility of house mouse.
Infertility, Male
PRDM Histone Methyltransferase mRNA Levels Increase in Response to Curative Hormone Treatment for Cryptorchidism-Dependent Male Infertility.
Inflammatory Bowel Diseases
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).
Influenza, Human
Transcriptional Derepression of the ERVWE1 Locus following Influenza A Virus Infection.
Insulin Resistance
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex.
Intellectual Disability
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
De novo loss-of-function variants of ASH1L are associated with an emergent neurodevelopmental disorder.
Derepression of inflammation-related genes link to microglia activation and neural maturation defect in a mouse model of Kleefstra syndrome.
Distinct Pathogenic Genes Causing Intellectual Disability and Autism Exhibit a Common Neuronal Network Hyperactivity Phenotype.
EHMT1 regulates Parvalbumin-positive interneuron development and GABAergic input in sensory cortical areas.
Epigenetic regulation in human brain-focus on histone lysine methylation.
Epigenetic regulation of learning and memory by Drosophila EHMT/G9a.
Euchromatin histone methyltransferase 1 regulates cortical neuronal network development.
Exon resequencing of H3K9 methyltransferase complex genes, EHMT1, EHTM2 and WIZ, in Japanese autism subjects.
First episode of psychosis in Kleefstra syndrome: a case report.
Functional convergence of histone methyltransferases EHMT1 and KMT2C involved in intellectual disability and autism spectrum disorder.
Haploinsufficiency of EHMT1 improves pattern separation and increases hippocampal cell proliferation.
Hippocampal dysfunction in the Euchromatin histone methyltransferase 1 heterozygous knockout mouse model for Kleefstra syndrome.
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Increased H3K9 methylation and impaired expression of Protocadherins are associated with the cognitive dysfunctions of the Kleefstra syndrome.
Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome.
Reduced exploration, increased anxiety, and altered social behavior: Autistic-like features of euchromatin histone methyltransferase 1 heterozygous knockout mice.
Reversible white matter lesions associated with mutant EHMT1 and Kleefstra syndrome.
RNA Sequencing and Pathway Analysis Identify Important Pathways Involved in Hypertrichosis and Intellectual Disability in Patients with Wiedemann-Steiner Syndrome.
Setd5 haploinsufficiency alters neuronal network connectivity and leads to autistic-like behaviors in mice.
The Object Space Task reveals increased expression of cumulative memory in a mouse model of Kleefstra syndrome.
Transcriptional consequences of 16p11.2 deletion and duplication in mouse cortex and multiplex autism families.
Intestinal Neoplasms
The epigenetic regulator Mll1 is required for Wnt-driven intestinal tumorigenesis and cancer stemness.
Ischemic Stroke
The progress of research on histone methylation in ischemic stroke pathogenesis.
Kidney Diseases
Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases.
The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1.
Kidney Neoplasms
Histone Methyltransferase G9a Promotes the Development of Renal Cancer through Epigenetic Silencing of Tumor Suppressor Gene SPINK5.
Lafora Disease
Early-onset Lafora body disease.
Language Development Disorders
Human subtelomeric copy number gains suggest a DNA replication mechanism for formation: beyond breakage-fusion-bridge for telomere stabilization.
Language Disorders
First episode of psychosis in Kleefstra syndrome: a case report.
Leiomyoma
The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
Leukemia
A higher-order configuration of the heterodimeric DOT1L-AF10 coiled-coil domains potentiates their leukemogenenic activity.
A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival.
An MLL-dependent network sustains hematopoiesis.
Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.
ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia.
Clathrin Assembly Lymphoid Myeloid Leukemia-AF10-positive Acute Leukemias: A Report of 2 Cases with a Review of the Literature.
Cyp33 binds AU-rich RNA motifs via an extended interface that competitively disrupts the gene repressive Cyp33-MLL1 interaction in vitro.
Decreased mixed lineage leukemia 1 is involved in endometriosis-related infertility.
Design of a fluorescent ligand targeting the S-adenosylmethionine binding site of the histone methyltransferase MLL1.
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.
Discovery of first-in-class inhibitors of ASH1L histone methyltransferase with anti-leukemic activity.
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Dual functions of histone-lysine N-methyltransferase Setdb1 protein at promyelocytic leukemia-nuclear body (PML-NB): maintaining PML-NB structure and regulating the expression of its associated genes.
Elements of the Polycomb repressor SU(Z)12 needed for histone H3-K27 methylation, the interface with E(Z), and in vivo function.
Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Epigenetic regulation of protein translation in KMT2A-rearranged AML.
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
Gene-specific patterns of coregulator requirements by estrogen receptor-? in breast cancer cells.
Genome-wide association and functional studies identify the DOT1L gene to be involved in cartilage thickness and hip osteoarthritis.
Global and Hox-specific roles for the MLL1 methyltransferase.
H3K9 methyltransferase G9a negatively regulates UHRF1 transcription during leukemia cell differentiation.
Histone Methylation Directs Myeloid TLR4 Expression and Regulates Wound Healing following Cutaneous Tissue Injury.
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer.
Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential.
Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation.
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
Inhibition of Dot1L Alleviates Fulminant Hepatitis Through Myeloid-Derived Suppressor Cells.
Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
Interaction of DNA demethylase and histone methyltransferase upregulates Nrf2 in 5-fluorouracil-resistant colon cancer cells.
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation.
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
lncRNA MIAT promotes cell invasion and migration in esophageal cancer.
Long noncoding RNA MIAT promotes non-small cell lung cancer proliferation and metastasis through MMP9 activation.
Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis.
Lysine methyltransferase G9a is required for de novo DNA methylation and the establishment, but not the maintenance, of proviral silencing.
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.
Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
MicroRNAs mark in the MLL-rearranged leukemia.
Misguided transcriptional elongation causes mixed lineage leukemia.
Mixed Lineage Leukemia 1 Promoted Neuron Apoptosis in Ischemic Penumbra via Regulating ASK-1/TNF-? Complex.
Mixed-lineage leukemia protein 2 suppresses ciliary assembly by the modulation of actin dynamics and vesicle transport.
MLL translocation in two castration-resistant prostate cancer patients.
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1.
MLL1 combined with GSK3 and MAP2K inhibition improves the development of in vitro-fertilized embryos.
MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-?B signaling pathway via H3K4me3 enrichment in the TLR4 promoter region.
MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia.
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
MLL: a histone methyltransferase disrupted in leukemia.
Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
NAD(+)-SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1.
Negative Regulation of JAK2 by H3K9 Methyltransferase G9a in Leukemia.
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
Pharmacologic Inhibition of the Menin-MLL Interaction Leads to Transcriptional Repression of
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity.
Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters.
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Regulated nuclear entry of over-expressed Setdb1.
Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk.
ROR? autoregulates its transcription via MLL4-associated enhancer remodeling in the liver.
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ?Np63? protein.
Solution NMR structure and histone binding of the PHD domain of human MLL5.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
SUV39H1 is a New Client Protein of Hsp90 Degradated by Chaetocin as a Novel C-Terminal Inhibitor of Hsp90.
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L.
Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development.
The epigenetic control of E-box and Myc-dependent chromatin modifications regulate the licensing of lamin B2 origin during cell cycle.
The Histone Methyltransferase DOT1L Is Essential for Humoral Immune Responses.
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
The Histone Methyltransferase Mixed Lineage Leukemia (MLL) 3 May Play a Potential Role on Clinical Dilated Cardiomyopathy.
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells.
The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3-9 combines domains of antagonistic regulators of homeotic gene complexes.
The STAT4/MLL1 Epigenetic Axis Regulates the Antimicrobial Functions of Murine Macrophages.
Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue.
[Effect of SUV39H1 siRNA Silence on Apoptosis and Proliferation of Acute Myelogenous Leukemia KG-1 Cell Line].
[Experimental study of SUV39H1 gene specific siRNA in human leukemia cell line].
Leukemia, Erythroblastic, Acute
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription.
The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture.
Leukemia, Lymphocytic, Chronic, B-Cell
Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.
Efficient and flexible Integration of variant characteristics in rare variant association studies using integrated nested Laplace approximation.
Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
The histone methyltransferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia.
Leukemia, Mast-Cell
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Leukemia, Myeloid
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
Leukemia, Myeloid, Acute
---Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia-.
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2.
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients.
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia.
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia.
PERK/NRF2 and autophagy form a resistance mechanism against G9a inhibition in leukemia stem cells.
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Quantitative proteomic analysis of EZH2 inhibition in acute myeloid leukemia reveals the targets and pathways that precede the induction of cell death.
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
The NIZP1 KRAB and C2HR domains cross-talk for transcriptional regulation.
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.
[Effect of SUV39H1 siRNA Silence on Apoptosis and Proliferation of Acute Myelogenous Leukemia KG-1 Cell Line].
Liver Cirrhosis
A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A.
A twenty gene-based gene set variation score reflects the pathological progression from cirrhosis to hepatocellular carcinoma.
Liver Neoplasms
Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Inactivation of lncRNA HOTAIRM1 caused by histone methyltransferase RIZ1 accelerated the proliferation and invasion of liver cancer.
Inhibition of histone methyltransferase G9a attenuates liver cancer initiation by sensitizing DNA-damaged hepatocytes to p53-induced apoptosis.
miR24-2 accelerates progression of liver cancer cells by activating Pim1 through tri-methylation of Histone H3 on the ninth lysine.
SETDB1 in cancer: overexpression and its therapeutic implications.
Lung Injury
Inhibition of EZH2 prevents acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis by regulating the macrophage polarization phenotype.
Lung Neoplasms
A regulatory circuitry comprising TP53, miR-29 family, and SETDB1 in non-small cell lung cancer.
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death.
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Elevated Metabolic Activity on (18)F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer.
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
Histone methyltransferase SETD1A participates in lung cancer progression.
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells.
Modulation of microRNA expression in human lung cancer cells by the G9a histone methyltransferase inhibitor BIX01294.
Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility.
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.
Lymphatic Metastasis
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan.
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Lymphoma
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type is associated with disease progression and prognosis.
Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma.
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
MLL/KMT2A translocations in diffuse large B-cell lymphomas.
Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Lymphoma, B-Cell
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Deregulation of H3K27 methylation in cancer.
EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells.
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B-cell lymphomas.
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Treating lymphoma is now a bit EZ-er.
Lymphoma, Follicular
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Lymphoma, Large B-Cell, Diffuse
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.
Deregulation of H3K27 methylation in cancer.
EHMT2 inhibitor BIX-01294 induces endoplasmic reticulum stress mediated apoptosis and autophagy in diffuse large B-cell lymphoma cells.
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.
Treating lymphoma is now a bit EZ-er.
Lymphoma, Large-Cell, Anaplastic
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Lymphoma, Mantle-Cell
JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Lymphoma, Non-Hodgkin
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma.
Studies Identify Non-Hodgkin Lymphoma Suppressor.
Lymphoma, T-Cell
Dual Role of EZH2 in Cutaneous Anaplastic Large Cell Lymphoma: Promoting Tumor Cell Survival and Regulating Tumor Microenvironment.
Oncogene-induced senescence as an initial barrier in lymphoma development.
Lymphopenia
Novel gene-specific translation mechanism of dysregulated, chronic inflammation reveals promising, multifaceted COVID-19 therapeutics.
Malaria
A histone methyltransferase inhibitor can reverse epigenetically acquired drug resistance in the malaria parasite Plasmodium falciparum.
Histone Methyltransferase Inhibitors Are Orally Bioavailable, Fast-Acting Molecules with Activity against Different Species Causing Malaria in Humans.
The Role of the Histone Methyltransferase PfSET10 in Antigenic Variation by Malaria Parasites: a Cautionary Tale.
Mastocytosis
Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells: Implications for Mastocytosis.
Medulloblastoma
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.
Melanoma
A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Androgen receptor regulation by histone methyltransferase Suppressor of variegation 3-9 homolog 2 and Melanoma antigen-A11.
BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases.
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP.
Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
G9a Is SETting the Stage for Colorectal Oncogenesis.
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3.
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
High frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression.
Mithramycin A and Mithralog EC-8042 Inhibit SETDB1 Expression and Its Oncogenic Activity in Malignant Melanoma.
Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
SETDB1 in cancer: overexpression and its therapeutic implications.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
SUV39H1/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development.
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.
Meningioma
The transducible TAT-RIZ1-PR protein exerts histone methyltransferase activity and tumor-suppressive functions in human malignant meningiomas.
Mesothelioma
CDKN2A Determines Mesothelioma Cell Fate to EZH2 Inhibition.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Mesothelioma, Malignant
Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Microcephaly
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
Movement Disorders
Variants in estrogen-related genes and risk of Parkinson's disease.
Multiple Endocrine Neoplasia
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Multiple Endocrine Neoplasia Type 1
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Multiple Myeloma
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma.
EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes.
H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.
Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.
Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis.
MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains.
The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.
The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma.
Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Unabridged Analysis of Human Histone H3 by Differential Top-Down Mass Spectrometry Reveals Hypermethylated Proteoforms from MMSET/NSD2 Overexpression.
Multiple Sclerosis
Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.
Muscle Hypotonia
A novel de novo frameshift deletion in EHMT1 in a patient with Kleefstra Syndrome results in decreased H3K9 dimethylation.
First episode of psychosis in Kleefstra syndrome: a case report.
Reduced Euchromatin histone methyltransferase 1 causes developmental delay, hypotonia, and cranial abnormalities associated with increased bone gene expression in Kleefstra syndrome mice.
Reversible white matter lesions associated with mutant EHMT1 and Kleefstra syndrome.
Muscular Dystrophies
FSHD muscular dystrophy region gene 1 binds Suv4-20h1 histone methyltransferase and impairs myogenesis.
Myelodysplastic Syndromes
Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2).
Decreased expression of PRDM2 (RIZ1) and its correlation with risk stratification in patients with myelodysplastic syndrome.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
RNA splicing, cell signaling, and response to therapies.
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
The role of histone methyltransferase EZH2 in myelodysplastic syndromes.
Myocardial Infarction
Role of Muscle-Specific Histone Methyltransferase (Smyd1) in Exercise-Induced Cardioprotection against Pathological Remodeling after Myocardial Infarction.
The combination of G9a histone methyltransferase inhibitors with erythropoietin protects heart against damage from acute myocardial infarction.
The histone H3K9 methyltransferase SUV39H links SIRT1 repression to myocardial infarction.
Myocardial Ischemia
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
Nasopharyngeal Carcinoma
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
SETDB1 in cancer: overexpression and its therapeutic implications.
Neoplasm Metastasis
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Analysis of methylation profiling data of hyperplasia and primary and metastatic endometrial cancers.
BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Dysregulation of the epigenetic regulator SETDB1 in liver carcinogenesis-more than one way to skin a cat.
DZNep inhibits Hif-1? and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
EHMT2 is a metastasis regulator in breast cancer.
Emerging role of SETDB1 as a therapeutic target.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
High expressions of histone methylation- and phosphorylation-related proteins are associated with prognosis of oral squamous cell carcinoma in male population of Taiwan.
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b.
Histone methyltransferase hSETD1A is a Novel Regulator of Metastasis in Breast Cancer.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer.
LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2/SNAI1 complex.
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.
Novel strategies for molecular targeting to cancer.
NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein.
Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Quantitative proteomic study of human prostate cancer cells with different metastatic potentials.
Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
SETDB1 induces epithelial?mesenchymal transition in breast carcinoma by directly binding with Snail promoter.
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
SETDB1 regulates SMAD7 expression for breast cancer metastasis.
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT.
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
The histone methyltransferase EZH2 promotes mammary stem and luminal progenitor cell expansion, metastasis and inhibits estrogen receptor-positive cellular differentiation in a model of basal breast cancer.
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Neoplasms
---Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia-.
20(S)-Ginsenoside Rh2 suppresses proliferation and migration of hepatocellular carcinoma cells by targeting EZH2 to regulate CDKN2A-2B gene cluster transcription.
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells.
5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation.
?Np63? modulates histone methyl transferase SETDB1 to transcriptionally repress target genes in cancers.
A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients.
A dimeric state for PRC2.
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
A fine balance: epigenetic control of cellular quiescence by the tumor suppressor PRDM2/RIZ at a bivalent domain in the cyclin a gene.
A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.
A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.
A Systematic Pan-Cancer Analysis of Genetic Heterogeneity Reveals Associations with Epigenetic Modifiers.
A TGF-?-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis.
Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type is associated with disease progression and prognosis.
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions.
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.
An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation.
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Analysis of somatic microsatellite indels identifies driver events in human tumors.
Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2.
Anticancer agents: Allosteric histone methyltransferase modulators block tumour growth.
Arsenic and benzo[a]pyrene co-exposure acts synergistically in inducing cancer stem cell-like property and tumorigenesis by epigenetically down-regulating SOCS3 expression.
Assignment of a novel bifurcated SET domain gene, SETDB1, to human chromosome band 1q21 by in situ hybridization and radiation hybrids.
Association of an miR-502-binding site polymorphism in the 3'-untranslated region of SET8 with colorectal cancer.
Association of Histone Methyltransferase G9a and Overall Survival After Liver Resection of Patients With Hepatocellular Carcinoma With a Median Observation of 40 Months.
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Biochemical Assay Development for Histone Methyltransferases Using a Transcreener-Based Assay for S-Adenosylhomocysteine.
BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production.
BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression.
BIX-01294, a G9a inhibitor, suppresses cell proliferation by inhibiting autophagic flux in nasopharyngeal carcinoma cells.
Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer.
Bone-in-culture array as a platform to model early-stage bone metastases and discover anti-metastasis therapies.
BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Cancer cells, on your histone marks, get SETDB1, silence retrotransposons, and go!
Cancer-associated fibroblasts enhance the migration ability of ovarian cancer cells by increasing EZH2 expression.
Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors.
Canonical and non-canonical roles of the histone methyltransferase EZH2 in mammary development and cancer.
Carcinogenesis of Intraductal Papillary Mucinous Neoplasm of the Pancreas: Loss of MicroRNA-101 Promotes Overexpression of Histone Methyltransferase EZH2.
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.
Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma.
Clinicopathological significance of G9A expression in colorectal carcinoma.
Combining epigenetic and immune therapy to overcome cancer resistance.
Commentary on Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM, Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109.
Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.
Cooperation between SMYD3 and PC4 drives a distinct transcriptional program in cancer cells.
Correction: Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
CRISPR/Cas9 mediated generation of a iPSC line EHTJUi005-A-1 with homozygous knockout of the SUV39H1 gene.
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression.
Cyclin-dependent Kinase 1 (CDK1)-mediated Phosphorylation of Enhancer of Zeste 2 (Ezh2) Regulates Its Stability.
Deficiency of G9a Inhibits Cell Proliferation and Activates Autophagy via Transcriptionally Regulating c-Myc Expression in Glioblastoma.
Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis.
Depletion of G9a gene induces cell apoptosis in human gastric carcinoma.
Depletion of histone methyltransferase KMT9 inhibits lung cancer cell proliferation by inducing non-apoptotic cell death.
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Differential expression of selected histone modifier genes in human solid cancers.
Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc/Bcl2 coexpression.
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.
DNA-PK-mediated phosphorylation of EZH2 regulates the DNA damage-induced apoptosis to maintain T-cell genomic integrity.
Dot1l expression predicts adverse postoperative prognosis of patients with clear-cell renal cell carcinoma.
DOTting the path to doom: how acceleration of histone methylation leads to leukemia.
Down-regulation of G9a triggers DNA damage response and inhibits colorectal cancer cells proliferation.
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells.
Dual epigenetic modifiers for cancer therapy.
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
DZNep inhibits Hif-1? and Wnt signalling molecules to attenuate the proliferation and invasion of BGC-823 gastric cancer cells.
E4BP4/NFIL3 modulates the epigenetically repressed Ras effector RASSF8 function through histone methyl transferases.
Effects of histone methyltransferase inhibition in endometriosis.
Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells.
EHMT1 knockdown induces apoptosis and cell cycle arrest in lung cancer cells by increasing CDKN1A expression.
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
EHMT2 promotes the pathogenesis of hepatocellular carcinoma by epigenetically silencing APC expression.
EHMT2/G9a Inhibits Aortic Smooth Muscle Cell Death by Suppressing Autophagy Activation.
Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
Emerging role of SETDB1 as a therapeutic target.
Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1.
Enhanced expression of SETDB1 possesses prognostic value and promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma.
Enhancer of zeste homolog 2 (EZH2) inhibitors.
Enhancer of zeste homolog 2 induces pulmonary artery smooth muscle cell proliferation.
Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
Epidrugs in the immunotherapy of cutaneous and uveal melanoma.
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer.
Epigenetic perspective into head and neck cancer through in silico gene expression profiling of histone lysine methyltransferases.
Epigenetic priming by EHMT1/EHMT2 in acute lymphoblastic leukemia induces TP53 and TP73 overexpression and promotes cell death.
Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.
Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma.
Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Euchromatic histone lysine methyltransferase 1 regulates cancer development in human gastric cancer by regulating E-cadherin.
Euchromatin histone methyltransferase II (EHMT2) regulates the expression of ras-related GTP binding C (RRAGC) protein.
Exosomal miR-101-3p and miR-423-5p inhibit medulloblastoma tumorigenesis through targeting FOXP4 and EZH2.
EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies.
EZH2 facilitates BMI1-dependent hepatocarcinogenesis through epigenetically silencing microRNA-200c.
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
EZH2 Protein Expression and Tumor Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene.
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
EZH2, an epigenetic driver of prostate cancer.
EZH2-inhibitor DZNep enhances apoptosis of renal tubular epithelial cells in presence and absence of cisplatin.
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
EZH2: a pivotal regulator in controlling cell differentiation.
EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
Fine-tuning AKT kinase activity through direct lysine methylation.
First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability.
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma.
Functional regulation of hypoxia inducible factor-1? by SET9 lysine methyltransferase.
Functional Role of G9a Histone Methyltransferase in Cancer.
G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
G9a Promotes Breast Cancer Recurrence through Repression of a Pro-inflammatory Program.
G9A promotes gastric cancer metastasis by upregulating ITGB3 in a SET domain-independent manner.
G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin.
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis.
Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors.
Genetic or pharmacologic blockade of enhancer of zeste homolog 2 inhibits the progression of peritoneal fibrosis.
Genome-wide screening and functional analysis identifies tumor suppressor long non-coding RNAs epigenetically silenced in hepatocellular carcinoma.
Genome-wide transcriptional profiling analysis reveals annexin A6 as a novel EZH2 target gene involving gastric cellular proliferation.
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model.
Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells.
H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM.
H3K9 histone methyltransferase, KMT1E/SETDB1, cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis.
H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression.
HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase.
High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma.
High SET Domain Bifurcated 1 (SETDB1) Expression Predicts Poor Prognosis in Breast Carcinoma.
High WHSC1L1 Expression Reduces Survival Rates in Operated Breast Cancer Patients with Decreased CD8+ T Cells: Machine Learning Approach.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats.
Histone H3K4 methyltransferase Mll1 regulates protein glycosylation and tunicamycin-induced apoptosis through transcriptional regulation.
Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Histone lysine methyltransferase, SUV39H1, promotes HCC progression and is negatively regulated by microRNA-125b.
Histone methyltransferase and drug resistance in cancers.
Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function.
Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Histone Methyltransferase G9a Promotes the Development of Renal Cancer through Epigenetic Silencing of Tumor Suppressor Gene SPINK5.
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.
Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4.
Histone Methyltransferase MLL1 Regulates MDR1 Transcription and Chemoresistance.
Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma.
Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.
Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma.
Histone Methyltransferase SETDB1 Promotes Colorectal Cancer Proliferation through the STAT1-CCND1/CDK6 Axis.
Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53.
Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer.
Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.
Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells.
Identification of a peptide inhibitor for the histone methyltransferase WHSC1.
Identification of druggable cancer driver genes amplified across TCGA datasets.
Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Identification of PRDM2 regulated genes in quiescent C2C12 myoblasts.
Identification of protoberberine alkaloids as novel histone methyltransferase G9a inhibitors by structure-based virtual screening.
Identification of somatic mutations in parathyroid tumors using whole-exome sequencing.
Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.
Impact of EZH2 Polymorphisms on Urothelial Cell Carcinoma Susceptibility and Clinicopathologic Features.
Impact of OGT deregulation on EZH2 target genes FOXA1 and FOXC1 expression in breast cancer cells.
Impaired IRE1 expression and XBP1 activation is a hallmark of GCB-DLBCL and contributes to tumor growth.
Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation.
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
In vivo administration of G9a inhibitor A366 decreases osteogenic potential of bone marrow-derived mesenchymal stem cells.
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.
Inactivation of a histone methyltransferase by mutations in human cancers.
Inactivation of the Euchromatic Histone-Lysine N-Methyltransferase 2 Pathway in Pancreatic Epithelial Cells Antagonizes Cancer Initiation and Pancreatitis-Associated Promotion by Altering Growth and Immune Gene Expression Networks.
Increased expression of G9A contributes to carcinogenesis and indicates poor prognosis in hepatocellular carcinoma.
Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.
Inhibition of EHMT2/G9a epigenetically increases the transcription of Beclin-1 via an increase in ROS and activation of NF-?B.
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Inhibition of G9a induces DUSP4-dependent autophagic cell death in head and neck squamous cell carcinoma.
Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.
Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis.
Inhibition of Nuclear Receptor Binding SET Domain 2/Multiple Myeloma SET Domain by LEM-06 Implication for Epigenetic Cancer Therapies.
Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway.
Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer.
Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Investigating the epi-miRNome: identification of epi-miRNAs using transfection experiments.
Involvement of EZH2, SUV39H1, G9a and associated molecules in pathogenesis of urethane induced mouse lung tumors: potential targets for cancer control.
Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance.
KMT2A histone methyltransferase contributes to colorectal cancer development by promoting cathepsin Z transcriptional activation.
KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer.
KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Knockdown of SET Domain, Bifurcated 1 suppresses head and neck cancer cell viability and wound-healing ability in vitro.
Knockdown of SETDB1 inhibits breast cancer progression by miR-381-3p-related regulation.
Knockout of SETDB1 gene using the CRISPR/cas-9 system increases migration and transforming activities via complex regulations of E-cadherin, ?-catenin, STAT3, and Akt.
Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression.
LINC00476 Suppresses the Progression of Non-Small Cell Lung Cancer by Inducing the Ubiquitination of SETDB1.
LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma.
Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3.
Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics.
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Menin links estrogen receptor activation to histone H3K4 trimethylation.
Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.
Metallothionein 1h Tumor Suppressor Activity in Prostate Cancer Is Mediated By Euchromatin Methyltransferase 1.
Metformin inhibits SUV39H1-mediated migration of prostate cancer cells.
Methylation of Aurora kinase A by MMSET reduces p53 stability and regulates cell proliferation and apoptosis.
Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation and genome instability.
Methyltransferase G9a promotes cervical cancer angiogenesis and decreases patient survival.
MicroRNA-621 Acts as a Tumor Radiosensitizer by Directly Targeting SETDB1 in Hepatocellular Carcinoma.
miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
MLL1 promotes cervical carcinoma cell tumorigenesis and metastasis through interaction with ?-catenin.
MMSET is dynamically regulated during cell-cycle progression and promotes normal DNA replication.
MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.
Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis.
MUC1-C activates EZH2 expression and function in human cancer cells.
Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond.
Multilevel Regulation of ?-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.
Mutation of cancer driver MLL2 results in transcription stress and genome instability.
Myc, Cdk2 and cellular senescence: Old players, new game.
Negative regulation of DAB2IP by Akt and SCFFbw7 pathways.
NNK-induced DNA methyltransferase 1 in lung tumorigenesis in A/J mice and inhibitory effects of (-)-epigallocatechin-3-gallate.
Novel insights into SMYD2 and SMYD3 inhibitors: from potential anti-tumoural therapy to a variety of new applications.
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation.
NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression.
NUT Midline Carcinoma: Morphoproteomic Characterization with Genomic and Therapeutic Correlates.
Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines.
Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia.
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Overexpression of SMYD3 in Ovarian Cancer is Associated with Ovarian Cancer Proliferation and Apoptosis via Methylating H3K4 and H4K20.
Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Pharmacological and transcriptional inhibition of the G9a histone methyltransferase suppresses proliferation and modulates redox homeostasis in human microvascular endothelial cells.
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage.
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Polycomb repressive complex 2 contributes to DNA double-strand break repair.
Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).
PRDM8 Exhibits Anti-Tumor Activities Toward Hepatocellular Carcinoma by Targeting NAP1L1.
Preclinical efficacy of ribavirin in SHH and group 3 medulloblastoma.
Precocious neuronal differentiation and disrupted oxygen responses in Kabuki syndrome.
Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.
Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma.
Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
Prolyl isomerase Pin1 negatively regulates the stability of SUV39H1 to promote tumorigenesis in breast cancer.
Promiscuous RNA binding by Polycomb repressive complex 2.
Promoter occupancy of MLL1 histone methyltransferase seems to specify the proliferative and apoptotic functions of E2F1 in a tumour microenvironment.
Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
Proteomic and functional genomic landscape of receptor tyrosine kinase and ras to extracellular signal-regulated kinase signaling.
Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells.
Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked.
Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model.
Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.
Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression.
Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2.
Regulation of the DNA Damage Response and Gene Expression by the Dot1L Histone Methyltransferase and the 53Bp1 Tumour Suppressor.
RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines.
RNA interference targeting against S100A4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells.
Role of Histone Lysine Methyltransferases SUV39H1 and SETDB1 in Gliomagenesis: Modulation of Cell Proliferation, Migration, and Colony Formation.
Role of STAT3 and Vitamin D Receptor in EZH2-mediated invasion of human colorectal cancer.
Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Roles of the EZH2 histone methyltransferase in cancer epigenetics.
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Selective binding of the PHD6 finger of MLL4 to histone H4K16ac links MLL4 and MOF.
SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin.
SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma.
SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma.
SETDB-1: A Potential Epigenetic Regulator in Breast Cancer Metastasis.
SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.
SETDB1 in cancer: overexpression and its therapeutic implications.
SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice.
SETDB1 modulates the differentiation of both the crystal cells and the lamellocytes in Drosophila.
SETDB1 Overexpression Sets an Intertumoral Transcriptomic Divergence in Non-small Cell Lung Carcinoma.
SETDB1 promotes gastric carcinogenesis and metastasis via upregulation of CCND1 and MMP9 expression.
SETDB1 promotes glioblastoma growth via CSF-1-dependent macrophage recruitment by activating the AKT/mTOR signaling pathway.
SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression.
SETDB1-Mediated Silencing of Retroelements.
SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation.
SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a tumor suppressor to an oncogenic driver.
Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma.
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer.
Smad3-mediated recruitment of the methyltransferase SETDB1/ESET controls
SMURF2 prevents detrimental changes to chromatin, protecting human dermal fibroblasts from chromosomal instability and tumorigenesis.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma.
SMYD3-associated pathway is involved in the anti-tumor effects of sulforaphane on gastric carcinoma cells.
Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT.
Structural and Functional Characterization of the Acidic Region from the RIZ Tumor Suppressor.
Structural basis for PRC2 engagement with chromatin.
Structure, Activity and Function of the SETDB1 Protein Methyltransferase.
Structures of Nahuoic Acids B-E Produced in Culture by a Streptomyces sp. Isolated from a Marine Sediment and Evidence for the Inhibition of the Histone Methyl Transferase SETD8 in Human Cancer Cells by Nahuoic Acid A.
Studies Identify Non-Hodgkin Lymphoma Suppressor.
Su(var)3-9, Enhancer of Zeste, and Trithorax Domain-Containing 5 Facilitates Tumor Growth and Pulmonary Metastasis through Up-Regulation of AKT1 Signaling in Breast Cancer.
Surveillance of Retroelement Expression and Nucleic-Acid Immunity by Histone Methyltransferase SETDB1.
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth.
SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion.
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex.
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Symphony of epigenetic and metabolic regulation-interaction between the histone methyltransferase EZH2 and metabolism of tumor.
Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway.
Targeting epigenetic machinery: Emerging novel allosteric inhibitors.
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity.
Targeting FBXO44/SUV39H1 elicits tumor cell-specific DNA replication stress and viral mimicry.
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Targeting histone methyltransferase EZH2 as cancer treatment.
Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1? and APC2 gene expression in non-small cell lung cancer.
Targeting of cyclin-dependent kinases in atypical teratoid rhabdoid tumors with multikinase inhibitor TG02.
Targeting Suppressor of Variegation 3-9 Homologue 2 (SUV39H2) in Acute Lymphoblastic Leukemia (ALL).
Targeting the Atf7ip-Setdb1 complex augments antitumor immunity by boosting tumor immunogenicity.
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
TERT promoter mutations in primary liver tumors.
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2,4-Diamino-7-aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies.
The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma.
The EZH2-PHACTR2-AS1-Ribosome Axis induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer.
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.
The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer.
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors.
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.
The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells.
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors.
The histone methyltransferase G9a: a new therapeutic target in biliary tract cancer.
The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1? Stability and Angiogenesis.
The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells.
The Histone Methyltransferase Smyd2 Is a Negative Regulator of Macrophage Activation by Suppressing Interleukin 6 (IL-6) and Tumor Necrosis Factor ? (TNF-?) Production.
The histone methyltransferase SMYD2 is a novel therapeutic target for the induction of apoptosis in ovarian clear cell carcinoma cells.
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
The hypoxia-inducible epigenetic regulators Jmjd1a and G9a provide a mechanistic link between angiogenesis and tumor growth.
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
The methylation profiles of PRDM promoters in non-small cell lung cancer.
The novel EZH2 inhibitor, GSK126, suppresses cell migration and angiogenesis via down-regulating VEGF-A.
The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
The polycomb group protein EZH2 is a novel therapeutic target for cervical cancer.
The predictive value of PRDM2 in solid tumor: a systematic review and meta-analysis.
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative Review.
The Pseudogene DUXAP8 Promotes Non-small-cell Lung Cancer Cell Proliferation and Invasion by Epigenetically Silencing EGR1 and RHOB.
The recruitment of chromatin modifiers by long noncoding RNAs: lessons from PRC2.
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
The Role of G9a in Tumorigenesis in Head and Neck Cancer.
The SMYD family proteins in immunology: An update of their obvious and non-obvious relations with the immune system.
The SRA protein UHRF1 promotes epigenetic crosstalks and is involved in prostate cancer progression.
The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.
The transcription factor GATA1 and the histone methyltransferase SET7 interact to promote VEGF-mediated angiogenesis and tumor growth and predict clinical outcome of breast cancer.
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis.
The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma.
Toward a Consensus on the Binding Specificity and Promiscuity of PRC2 for RNA.
Transcription analysis of a histones modifiers panel coupled with critical tumor suppressor genes displayed frequent changes in patients with AML.: mRNA levels of histones modifiers and TSGs in AML.
Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence.
Two Loops Undergoing Concerted Dynamics Regulate the Activity of the ASH1L Histone Methyltransferase.
Unique Role of Histone Methyltransferase PRDM8 in the Tumorigenesis of Virus-Negative Merkel Cell Carcinoma.
Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Using S-adenosyl-L-homocysteine capture compounds to characterize S-adenosyl-L-methionine and S-adenosyl-L-homocysteine binding proteins.
Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy.
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired Histone Methyltransferase Function In Vitro.
Whole-exome sequencing identifies variants in invasive pituitary adenomas.
Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers.
Wolf-Hirschhorn syndrome candidate 1 facilitates alveolar macrophage pyroptosis in sepsis-induced acute lung injury through NEK7-mediated NLRP3 inflammasome activation.
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
[An update on epigenetic regulator gene mutations and pathogenesis of myelodysplasic syndromes].
[Inhibition of SMYD3 gene expression by RNA interference induces apoptosis in human hepatocellular carcinoma cell line HepG2]
[The significance of histone modifications in malignant transformation].
Neoplasms, Germ Cell and Embryonal
Critical Function of PRDM2 in the Neoplastic Growth of Testicular Germ Cell Tumors.
Neoplasms, Squamous Cell
Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer.
Nervous System Diseases
Structural and functional annotation of PR/SET Domain (PRDM) protein family: In-silico study elaborating role of PRDM12 mutation in congenital insensitivity to pain.
Neuralgia
Downregulation of a Dorsal Root Ganglion-Specifically Enriched Long Noncoding RNA is Required for Neuropathic Pain by Negatively Regulating RALY-Triggered Ehmt2 Expression.
Histone methyltransferase G9a diminishes expression of cannabinoid CB1 receptors in primary sensory neurons in neuropathic pain.
N6-Methyladenosine Demethylase FTO Contributes to Neuropathic Pain by Stabilizing G9a Expression in Primary Sensory Neurons.
Neuroblastoma
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma.
Correction: Inhibition of H3K9 Methyltransferase G9a Repressed Cell Proliferation and Induced Autophagy in Neuroblastoma Cells.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
Enhancer of zeste homologue 2 plays an important role in neuroblastoma cell survival independent of its histone methyltransferase activity.
Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma.
Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.
Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma.
Inhibition of H3K9 methyltransferase G9a repressed cell proliferation and induced autophagy in neuroblastoma cells.
Oxidative stress-induced aberrant G9a activation disturbs RE-1-containing neuron-specific genes expression, leading to degeneration in human SH-SY5Y neuroblastoma cells.
Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells.
The histone methyltransferase DOT1L promotes neuroblastoma by regulating gene transcription.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Non-alcoholic Fatty Liver Disease
The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice.
Obesity
ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
Correction to: ALDH2 protects against high fat diet-induced obesity cardiomyopathy and defective autophagy: role of CaM kinase II, histone H3K9 methyltransferase SUV39H, Sirt1, and PGC-1? deacetylation.
EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex.
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
The Histone Methyltransferase MLL1 Directs Macrophage-Mediated Inflammation in Wound Healing and Is Altered in a Murine Model of Obesity and Type 2 Diabetes.
Osteoarthritis
Expression and function of EZH2 in synovial fibroblasts: epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis.
EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis.
The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/?-catenin pathway.
Osteoporosis
The histone methyltransferase DOT1L inhibits osteoclastogenesis and protects against osteoporosis.
Osteosarcoma
Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2.
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.
Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/?-catenin signaling.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma.
Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.
SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma.
Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.
Ovarian Neoplasms
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells.
Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
EHMT2 Inhibition Induces Cell Death in Human Non-Small Cell Lung Cancer by Altering the Cholesterol Biosynthesis Pathway.
EZH2 participates in malignant biological behavior of epithelial ovarian cancer through regulating the expression of BRCA1.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.
Ketamine Inhibits Ovarian Cancer Cell Growth by Regulating the lncRNA-PVT1/EZH2/p57 Axis.
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.
The Histone Methyltransferase DOT1L Is a Functional Component of Estrogen Receptor Alpha Signaling in Ovarian Cancer Cells.
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
Pancreatic Neoplasms
Preprogramming therapeutic response of PI3K/mTOR dual inhibitor via the regulation of EHMT2 and p27 in pancreatic cancer.
S100A4 is frequently overexpressed in lung cancer cells and promotes cell growth and cell motility.
SUV420H2 is an epigenetic regulator of epithelial/mesenchymal states in pancreatic cancer.
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Parkinson Disease
Variants in estrogen-related genes and risk of Parkinson's disease.
Peritoneal Fibrosis
Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis.
Persistent Infection
Targeting p53 and histone methyltransferases restores exhausted CD8+ T cells in HCV infection.
Pituitary Neoplasms
Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.
The absence of PRDM2 involved the tumorigenesis of somatotroph adenomas through regulating c-Myc.
Prader-Willi Syndrome
Histone lysine methyltransferase SETDB1 as a novel target for central nervous system diseases.
Reactivation of maternal SNORD116 cluster via SETDB1 knockdown in Prader-Willi syndrome iPSCs.
Role of histone methyltransferase G9a in CpG methylation of the Prader-Willi syndrome imprinting center.
Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader-Willi syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.
Epigenetic approaches in glioblastoma multiforme and their implication in screening and diagnosis.
Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Progeria
Depleting the methyltransferase Suv39h1 improves DNA repair and extends lifespan in a progeria mouse model.
Prolactinoma
Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature.
Prostatic Hyperplasia
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Prostatic Neoplasms
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.
Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as a driving force for prostate cancer development.
EHMT2 promotes the development of prostate cancer by inhibiting PI3K/AKT/mTOR pathway.
EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.
EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.
EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
EZH2, an epigenetic driver of prostate cancer.
Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer.
Histone methyltransferase NSD2/MMSET mediates constitutive NF-?B signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer.
Histone Methyltransferase Setd7 Regulates Nrf2 Signaling Pathway by Phenethyl Isothiocyanate and Ursolic Acid in Human Prostate Cancer Cells.
Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion.
Histone Methyltransferase SETDB1: A Common Denominator of Tumorigenesis with Therapeutic Potential.
Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation.
Identification of Differentially Methylated Regions Associated with a Knockout of SUV39H1 in Prostate Cancer Cells.
KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells.
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Novel strategies for molecular targeting to cancer.
Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription.
SETDB1 in cancer: overexpression and its therapeutic implications.
SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells.
Tandem histone methyltransferase upregulation defines a unique aggressive prostate cancer phenotype.
The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
The Inhibition of the Histone Methyltransferase EZH2 by DZNEP or SiRNA Demonstrates Its Involvement in MGMT, TRA2A, RPS6KA2, and U2AF1 Gene Regulation in Prostate Cancer.
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
Transcriptomic Analysis of Histone Methyltransferase Setd7 Knockdown and Phenethyl Isothiocyanate in Human Prostate Cancer Cells.
Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells.
Pseudorabies
Association of multi-pathogenic infections with BAT2, CXCL12, Mx1 and EHMT2 variations in pigs.
Psoriasis
Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris.
Pulmonary Disease, Chronic Obstructive
An efficient hybrid feature selection method to identify potential biomarkers in common chronic lung inflammatory diseases.
Corrigendum: SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.
SUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.
Reperfusion Injury
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
Suv39h1 protects from myocardial ischemia-reperfusion injury in diabetic rats.
The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1.
Retinoblastoma
Diverse roles of WDR5-RbBP5-ASH2L-DPY30 (WRAD) complex in the functions of the SET1 histone methyltransferase family.
Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines.
Loss of RB compromises specific heterochromatin modifications and modulates HP1alpha dynamics.
Rb targets histone H3 methylation and HP1 to promoters.
Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase.
Rhabdoid Tumor
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Rhabdomyosarcoma, Alveolar
Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state.
Stuck in a balancing act: histone methyltransferase activity of KMT1A traps alveolar rhabdomyosarcomas in an undifferentiated state.
The Histone Methyltransferase Gene G9A Is Regulated by Nuclear Receptor 4A1 in Alveolar Rhabdomyosarcoma Cells.
Rhabdomyosarcoma, Embryonal
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
The histone methyltransferase SUV39H1 suppresses embryonal rhabdomyosarcoma formation in zebrafish.
Rheumatic Diseases
EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis.
Sarcoma
Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.
Sarcoma, Ewing
Identification of driver genes associated with chemotherapy resistance of Ewing's sarcoma.
Scleroderma, Systemic
Genome-wide DNA methylation analysis in blood cells from patients with Werner syndrome.
Scoliosis
Suv39h1 promotes facet joint chondrocyte proliferation by targeting miR-15a/Bcl2 in idiopathic scoliosis patients.
Sepsis
Dynamic and selective nucleosome repositioning during endotoxin tolerance.
Inhibition of EZH2 prevents acute respiratory distress syndrome (ARDS)-associated pulmonary fibrosis by regulating the macrophage polarization phenotype.
Lymphocyte expression of EZH2 is associated with mortality and secondary infectious complications in sepsis.
Novel pharmacological inhibition of EZH2 attenuates septic shock by altering innate inflammatory responses to sepsis.
Severe Acute Respiratory Syndrome
Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2.
Skin Neoplasms
Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer.
Small Cell Lung Carcinoma
Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Sotos Syndrome
19p13.2 microduplication causes a Sotos syndrome-like phenotype and alters gene expression.
Co-occurrence of a maternally inherited DNMT3A duplication and a paternally inherited pathogenic variant in EZH2 in a child with growth retardation and severe short stature: atypical Weaver syndrome or evidence of a DNMT3A dosage effect?
Decreased serum dependence in the growth of NIH3T3 cells from the overexpression of human nuclear receptor-binding SET-domain-containing protein 1 (NSD1) or fission yeast su(var)3-9, enhancer-of-zeste, trithorax 2 (SET2).
Disrupted epigenetics in the Sotos syndrome neurobehavioral phenotype.
Growth disrupting mutations in epigenetic regulatory molecules are associated with abnormalities of epigenetic aging.
Hypoparathyroidism in a 3-year-old Korean boy with Sotos syndrome and a novel mutation in NSD1.
Investigating cortical features of Sotos syndrome using mice heterozygous for Nsd1.
NSD1 mutations generate a genome-wide DNA methylation signature.
Screening for genes that accelerate the epigenetic aging clock in humans reveals a role for the H3K36 methyltransferase NSD1.
Sotos syndrome.
Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort.
The Structure of NSD1 Reveals an Autoregulatory Mechanism Underlying Histone H3K36 Methylation.
Squamous Cell Carcinoma of Head and Neck
Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation.
Histone methyltransferase G9a drives chemotherapy resistance by regulating the glutamate-cysteine ligase catalytic subunit in head and neck squamous cell carcinoma.
Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma.
Upregulation of histone methyltransferase, DOT1L by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma.
Starvation
A metabolic throttle regulates the epigenetic state of rDNA.
Epigenetic regulation of starvation-induced autophagy in Drosophila by histone methyltransferase G9a.
Ischemic Preconditioning Confers Epigenetic Repression of Mtor and Induction of Autophagy Through G9a-Dependent H3K9 Dimethylation.
lncRNA recruits RNAi and the exosome to dynamically regulate pho1 expression in response to phosphate levels in fission yeast.
Regulation of Epigenetic Modifiers, Including KDM6B, by Interferon-? and Interleukin-4 in Human Macrophages.
Stomach Diseases
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
Stomach Neoplasms
Aberrant histone methylation and the effect of Suv39H1 siRNA on gastric carcinoma.
ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells.
Effects of miR-362 in Regulating the Proliferation, Invasion and Apoptosis of Gastric Cancer by Inhibiting the Expression of Tumor-Promoting Factor PRDM2.
Epigenetic alterations of gastrokine 1 gene expression in gastric cancer.
Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer.
Histone methyltransferase SETD1A interacts with HIF1? to enhance glycolysis and promote cancer progression in gastric cancer.
Increased expression of EHMT2 associated with H3K9me2 level contributes to the poor prognosis of gastric cancer.
LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern.
Oncogenic roles of the SETDB2 histone methyltransferase in gastric cancer.
Retraction: Epigenetic silenced miR-125a-5p could be self-activated through targeting Suv39H1 in gastric cancer.
SETDB2 promoted breast cancer stem cell maintenance by interaction with and stabilization of ?Np63? protein.
The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Thyroid Cancer, Papillary
Histone methyltransferase KMT5A gene modulates oncogenesis and lipid metabolism of papillary thyroid cancer in vitro.
Thyroid Carcinoma, Anaplastic
Novel role of ASH1L histone methyltransferase in anaplastic thyroid carcinoma.
Triple Negative Breast Neoplasms
Association Between Histone Methyltransferase hSETD1A and Prognosis in Patients With Triple-Negative Breast Cancer After Surgery: A Retrospective Study in the Chinese Female Population.
Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling.
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Targeting Histone Methyltransferase DOT1L by a Novel Psammaplin A Analog Inhibits Growth and Metastasis of Triple-Negative Breast Cancer.
ulp1 peptidase deficiency
Senp2 Regulates Adipose Lipid Storage by De-SUMOylation of Setdb1.
Urinary Bladder Neoplasms
Chaetocin Abrogates the Self-Renewal of Bladder Cancer Stem Cells via the Suppression of the KMT1A-GATA3-STAT3 Circuit.
EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.
Methylation of a Novel Panel of Tumor Suppressor Genes in Urine Moves Forward Non-Invasive Diagnosis and Prognosis in Bladder Cancer: A Two Center Prospective Study.
Methylation of tumor suppressor genes in a novel panel predicts clinical outcome in paraffin-embedded bladder tumors.
The KMT1A-GATA3-STAT3 circuit is a novel self-renewal signaling of human bladder cancer stem cells.
Uterine Cervical Neoplasms
A SUV39H1-low chromatin state characterises and promotes migratory properties of cervical cancer cells.
Inhibition of Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) Suppresses the Proliferation and Invasion of Cervical Cancer Cells.
Novel strategies for molecular targeting to cancer.
Prognostic significance of histone methyltransferase enhancer of zeste homolog 2 in patients with cervical squamous cell carcinoma.
SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.
SUV39H1-Mediated DNMT1 is Participated in the Epigenetic Regulation of Smad3 in Cervical Cancer.
The polycomb group protein EZH2 is a novel therapeutic target for cervical cancer.
Vascular Diseases
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
Vascular System Injuries
Down-regulation of Suv39h1 attenuates neointima formation after carotid artery injury in diabetic rats.
Suv39h1 downregulation inhibits neointimal hyperplasia after vascular injury.
Vesicular Stomatitis
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
Virus Diseases
Epigenetic control of Foxp3 by SMYD3 H3K4 histone methyltransferase controls iTreg development and regulates pathogenic T-cell responses during pulmonary viral infection.
Inhibition of EHMT2 Induces a Robust Antiviral Response Against Foot-and-Mouth Disease and Vesicular Stomatitis Virus Infections in Bovine Cells.
The epigenetic regulator G9a mediates tolerance to RNA virus infection in Drosophila.
The histone methyltransferase EZH2 primes the early differentiation of follicular helper T cells during acute viral infection.
Wiskott-Aldrich Syndrome
Gene regulation of Wiskott-Aldrich syndrome protein and the human homolog of the Drosophila Su(var)3-9: WASP and SUV39H1, two adjacent genes at Xp11.23.
Wolf-Hirschhorn Syndrome
H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres.
Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway.
Retinoic acid inhibits histone methyltransferase Whsc1 during palatogenesis.
The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation.
The histone methyltransferase Wolf-Hirschhorn syndrome candidate 1-like 1 (WHSC1L1) is involved in human carcinogenesis.
WHSC1 links transcription elongation to HIRA-mediated histone H3.3 deposition.
WHSC1/NSD2 regulates immune infiltration in prostate cancer.
Wolf-Hirschhorn syndrome candidate 1 facilitates alveolar macrophage pyroptosis in sepsis-induced acute lung injury through NEK7-mediated NLRP3 inflammasome activation.
[histone h3]-lysine9 n-trimethyltransferase deficiency
An HP1 isoform-specific feedback mechanism regulates Suv39h1 activity under stress conditions.
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Euchromatin histone methyltransferase 1 regulates cortical neuronal network development.
Histone methyltransferase Suv39h1 deficiency prevents Myc-induced chromosomal instability in murine myeloid leukemias.
Maternal Setdb1 Is Required for Meiotic Progression and Preimplantation Development in Mouse.
Neuronal network dysfunction in a model for Kleefstra syndrome mediated by enhanced NMDAR signaling.
Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells.
SETDB1-Mediated Cell Fate Transition between 2C-Like and Pluripotent States.
SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis.
SUV39H1 mediated SIRT1 trans-repression contributes to cardiac ischemia-reperfusion injury.
The Histone Methyltransferase SETDB1 Modulates Survival of Spermatogonial Stem/Progenitor Cells Through NADPH Oxidase.